Status:

COMPLETED

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Lead Sponsor:

Bionomics Limited

Conditions:

Social Anxiety Disorder

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The purpose of the study is to evaluate the effect of a single, acute dose of BNC210 compared to placebo on reducing the severity of anxiety provoked by a behavioral assessment task and measured using...

Detailed Description

This is a randomized, double-blind, placebo-controlled, 2-arm, parallel-group, multi-center study. Participants will attend a Screening Visit to confirm eligibility and then return to the clinic withi...

Eligibility Criteria

Inclusion

  • A current diagnosis of social anxiety disorder as defined in the DSM-5.
  • A Liebowitz Social Anxiety Scale total score of ≥60.
  • Suitable contraception use in line with protocol requirements.
  • Ability to swallow tablets.

Exclusion

  • History of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorders, anorexia or bulimia, body dysmorphic disorder, PTSD, autism-spectrum disorder or obsessive-compulsive disorder, or any other Axis I or II disorder which is currently the primary focus of treatment over social anxiety disorder.
  • Hamilton Rating Scale for Depression score of ≥18.
  • Moderate or severe alcohol-use disorder, or any other substance-use disorder (any severity) in the past 12 months.
  • Use of psychotropic medications within 30 days of screening. Daily use of benzodiazepines within 90 days of screening.
  • Any clinically significant medical history or findings as determined by the Investigator that could interfere with the objectives of the study or put the participant at risk.

Key Trial Info

Start Date :

August 6 2024

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 19 2025

Estimated Enrollment :

370 Patients enrolled

Trial Details

Trial ID

NCT06510504

Start Date

August 6 2024

End Date

September 19 2025

Last Update

October 24 2025

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

AFFIRM-1 Study Site

Encino, California, United States, 91316

2

AFFIRM-1 Study Site

La Jolla, California, United States, 92037

3

AFFIRM-1 Study Site

Los Angeles, California, United States, 90025

4

AFFIRM-1 Study Site

Oceanside, California, United States, 92056